Access count of this item: 37

Files in This Item:
File Description SizeFormat 
journal.pone.0216139.pdf3.04 MBAdobe PDFView/Open
Title: An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes
Authors: Furutani, Yutaka
Toguchi, Mariko
Shiozaki-Sato, Yumi
Qin, Xian-Yang
Ebisui, Etsuko
Higuchi, Shoko
Sudoh, Masayuki
Suzuki, Harukazu
Takahashi, Nobuaki
Watashi, Koichi
Wakita, Takaji
Kakeya, Hideaki
Kojima, Soichi
Author's alias: 古谷, 裕
戸口, 真理子
戎井, 悦子
樋口, 祥子
須藤, 正幸
鈴木, 治和
髙橋, 伸明
渡士, 幸一
脇田, 隆字
掛谷, 秀昭
小嶋, 聡一
Issue Date: 12-Jun-2019
Publisher: Public Library of Science (PLoS)
Journal title: PLOS ONE
Volume: 14
Issue: 6
Thesis number: e0216139
Abstract: Oral administration of nucleotide analogues and injection of interferon-α (IFNα) are used to achieve immediate suppression in replication of hepatitis B virus (HBV). Nucleotide analogs and IFNα inhibit viral polymerase activity and cause long-term eradication of the virus at least in part through removing covalently closed circular DNA (cccDNA) via induction of the APOBEC3 deaminases family of molecules, respectively. This study aimed to explore whether the orally administrable low molecular weight agent CDM-3008 (RO8191), which mimics IFNα through the binding to IFNα/β receptor 2 (IFNAR2) and the activation of the JAK/STAT pathway, can suppress HBV replication and reduce cccDNA levels. In primary cultured human hepatocytes, HBV DNA levels were decreased after CDM-3008-treatment in a dose-dependent manner with a half-maximal inhibitory concentration (IC50) value of 0.1 μM, and this was accompanied by significant reductions in cellular cccDNA levels, both HBeAg and HBsAg levels in the cell culture medium. Using a microarray we comprehensively analyzed and compared changes in gene (mRNA) expression in CDM-3008- and IFNα-treated primary cultured human hepatocytes. As reported previously, CDM-3008 mimicked the induction of genes that participate in the interferon signaling pathway. OAS1 and ISG20 mRNA expression was similarly enhanced by both CDM-3008 and IFNα. Thus, CDM-3008 could suppress pgRNA expression to show anti-HBV activity. APOBEC3F and 3G mRNA expression was also induced by CDM-3008 and IFNα treatments, suggesting that cccDNA could be degraded through induced APOBEC3 family proteins. We identified the genes whose expression was specifically enhanced in CDM-3008-treated cells compared to IFNα-treated cells. The expression of SOCS1, SOCS2, SOCS3, and CISH, which inhibit STAT activation, was enhanced in CDM-3008-treated cells suggesting that a feedback inhibition of the JAK/STAT pathway was enhanced in CDM-3008-treated cells compared to IFNα-treated cells. In addition, CDM-3008 showed an additive effect with a clinically-used nucleoside entecavir on inhibition of HBV replication. In summary, CDM-3008 showed anti-HBV activity through activation of the JAK/STAT pathway, inducing the expression of interferon-stimulated genes (ISGs), with greater feedback inhibition than IFNα.
Description: B型肝炎ウイルス抑制物質の作用機序解明 --新規抗B型肝炎治療薬の開発へ期待--. 京都大学プレスリリース. 2019-06-13.
Rights: © 2019 Furutani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
URI: http://hdl.handle.net/2433/241748
DOI(Published Version): 10.1371/journal.pone.0216139
Related Link: http://www.kyoto-u.ac.jp/ja/research/research_results/2019/190613_1.html
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.